

Pfizer Switzerland: Methodology note for HCP/HCO disclosure 2025

Data year: 2025

Year of publication: 2026

Introduction – Pfizer’s Commitment to Transparency Reporting

We regularly work with healthcare professionals (HCPs) and healthcare organisations (HCOs) who advise us on a range of topics such as medicines development, the role of a medicine in a patient treatment pathway; health economics and clinical best practice. These working relationships are essential to gaining the real-world information we need in order to deliver treatment choices that improve the health of patients and to share information that may be relevant to clinical decision making.

We are committed to transparency about how we operate as a business and about the relationships we have with HCPs and HCOs. Sharing information about these relationships in a straightforward and open way will, we hope, help explain the critical value these relationships bring to patient management.

We believe that transparency is essential to building and maintaining confidence in us and in our medicines and strongly support the work being done by The European Federation of Pharmaceutical Industries and Associations (EFPIA) to improve transparency across the pharmaceutical industry.

This methodological note presents how the transfers of value are categorized and in what format they are disclosed.

Table of Contents

1. DEFINITIONS.....	4
2. DISCLOSURE'S SCOPE	7
3. SPECIFIC CONSIDERATIONS	8
4. DATA PROTECTION LEGAL BASIS.....	8
5. FORM OF DISCLOSURE	8
6. DISCLOSURE OF FINANCIAL DATA.....	9
7. ADDITIONAL INFORMATION.....	9

1. Definitions

1.1. Recipients:

HCPs *Healthcare professionals*: physicians, dentists and pharmacists who are working in particular in a practice or hospital together with pharmacists active in retail businesses and persons who are authorised by the Swiss law on therapeutic products to prescribe, deliver, and/or administer prescription-only medicinal products for humans. This definition also includes official representatives and persons with a public-law employment contract or mandate if they perform or are authorised to perform such activities.

HCOs *Healthcare organisations*: legal entities under private and public law as well as companies, sole proprietorships or other entities that are not specifically regulated in legal terms who employ healthcare professionals. These in particular include institutions, organisations, associations or other groups of healthcare professionals who provide healthcare services or consultancy or other services in healthcare (e.g. hospitals, clinics, foundations, universities or other educational establishments, scientific societies or professional associations, community practices or networks, but not patient organisations).

Recipients of pecuniary benefits: HCPs or HCOs together with patient organisations who have their primary practice or definitive business address or their registered office in Switzerland.

PO/PAG *Patient organisations*: not-for-profit organisations (including the organisations to which they are affiliated) based or active in Switzerland, which consist primarily of patients or their carers and which represent or support the needs of patients or their carers. This definition also includes persons who represent and/or formulate the collective concerns and interests of a patient organisation about a specific topic or a specific pathology.

Retired HCPs: ToVs of retired HCPs are not published

Deceased HCPs: ToVs of deceased HCPs are not published

1.2. Kind of ToVs:

ToV *Transfer of Value/Pecuniary benefits (general)*: in cash, as non-cash contributions, donations, grants or payments made either directly or indirectly in some other form for consultancy tasks or services, research and development, event support, advertising, sales or other purposes, always in connection with prescription-only medicinal products.

Direct ToVs are those which Pfizer provides directly to a particular recipient.

Indirect TOVs are those which a third party provides for a recipient in the name or on behalf of Pfizer, whereby the identity of Pfizer is known or recognisable to the recipient.

Transfer of Value Categories

The following table defines which transfers of value are reported in which EFPIA category and subcategory.

EFPIA category	EFPIA subcategory	Example Activities
Donations and Grants (HCOs only)	n/a	<ul style="list-style-type: none"> • Charitable contributions • Business Donations • Educational grants (e.g. fellowships, courses provided by an HCO where Pfizer does not select the individual HCPs participating) • Sponsoring of speakers/faculty which, by nature of purpose and funding are classified under educational grants
Contribution to Cost of Events	Sponsorship agreements (HCOs only)	<ul style="list-style-type: none"> • Placement of a brand logo in a conference programme or invitation communication in exchange for supporting the programme • Funding an event in return for a display booth • Funding an event in exchange for advertising space • Other advertising space (in paper, electronic or other format) • Satellite symposia at a congress • If part of a package: Name badges, drinks, meals etc. provided by the organisers (included in the sponsorship agreement) • Any other activity qualified as “Corporate Sponsorship” according to Pfizer’s Anti-Corruption Policies • Sponsoring of speaker/faculty and sponsoring courses provided by an HCO which are qualified as “Corporate Sponsorship” according to Pfizer’s Anti-Corruption Policies • For contributions provided to events through Professional Conference Organisers (PCOs): ToVs through PCOs are reported as follows: <ul style="list-style-type: none"> - either in the name of benefiting HCO - or in the name of recipient PCO
	Registration fees	<ul style="list-style-type: none"> • Registration fees paid for the HCP/HCO to attend events
	Travel & Accommodation	<ul style="list-style-type: none"> • Travel (e.g. flight, train, taxi, car hires, tolls, mileage reimbursement, parking, shared ground transportation) • Accommodation • Travel visa
Fee for services and consultancy	Fees	<ul style="list-style-type: none"> • Speaker engagements • Advisory Boards* • Study-related engagements • Preceptorships • Post-marketing surveillance studies

		<ul style="list-style-type: none"> • Non-Interventional Studies that are retrospective in nature • Medical writing • Data analysis • Development of education materials • General consulting / advising • Speaker training if linked to a speaker engagement • Any other activity which qualifies as General Consultancy according to Pfizer's Anti-Corruption Policies
	Related expenses	<ul style="list-style-type: none"> • Travel (e.g. flight, train, taxi, car hires, tolls, mileage reimbursement, parking) • Accommodation • Travel visa
Research and Development Transfers of Value	n/a	<ul style="list-style-type: none"> • Clinical Trials • Data Monitoring Committees related to studies • Non-Interventional Studies that are prospective in nature • Investigators Initiated Research (IIR) • Investigator Sponsored Research (ISR) • Clinical & Research Collaborations

* excluding Data Monitoring Committees related to studies which are disclosed in aggregate under R&D

2. Disclosure's Scope

- 2.1. Products concerned:** This report includes ToVs related to prescription-only medicines.
- 2.2. Company concerned:** This report includes ToVs processed by Pfizer Switzerland legal entities and includes ToVs from all Pfizer legal entities.
- 2.3. Excluded ToVs:** no reportable ToVs as defined by the Code have been excluded.
- 2.4. ToVs Date:** This report includes ToVs related to the reporting period for 2025.
- 2.5. Direct ToVs:** the clearing date is the reportable date.
- 2.6. Indirect ToVs:** the clearing date is the reportable date.
- 2.7. Non-monetary ToVs:** meeting or event: end date is the reportable date; benefit in kind donation: contract signature date is the reportable date.
- 2.8. ToVs in case of partial attendances or cancellation and refund:**
- Cancellation fees are not reported
 - No-shows are not reported if Pfizer is unable to confirm the in-kind benefit was received
- 2.9. Cross-border activities:** The disclosure report includes ToVs to HCPs and HCOs who practice in the disclosure report country. This includes all ToVs (direct and indirect) made by any Pfizer affiliates.
- 2.10. (R&D):** see section 1.2, Transfer of Value Categories.
- 2.11. Voluntary disclosure:** n/a

3. Specific considerations

3.1. Country unique identifier: n/a

3.2. Self-incorporated HCP: Self-incorporated HCPs are disclosed as HCPs irrespective of their legal or organisational form.

3.3. Multi-year agreements: Where contracts are valid for more than one year, each individual TOV is captured and disclosed in the reportable disclosure period.

3.4. Country specificities: according to the decision made by the Pharma-Code Commission in April 2018, Pfizer Switzerland decided not to disclose any transfer of values to international organizations based in Switzerland with focus on non-profit services in the health sector (for example: WHO, UNHCR, IFRC, GAVI etc.). These are specialized institutions for which disclosure of transfer of values under the PCC disclosure code does not seem reasonable in view of the sense and purpose of the Transparency Initiative. The respective organizations disclose potential cooperation directly.

3.5. Quality checks: In compliance with our global SOP

4. Data protection legal basis

4.1. Consent collection: Pfizer Switzerland discloses the TOV based on the consent of the HCPs to the disclosure of the TOVs made to them. If the recipients consent to disclosure, the sum of all ToV to that HCP during the reporting period is disclosed under their name. The Pfizer EEA/Switzerland HCP Privacy Notice is available under the following link: <https://privacycenter.pfizer.com/en/hcp-sw>. We make our best effort to advocate for transparency and explain its societal benefits.

If the covered recipient has not provided consent (i.e., consent has been revoked), the TOV are disclosed in the aggregate section of the report. This means that the transfer of value is not disclosed under their name, but as part of the sum of all the TOV.

4.2. Legitimate interest: n/a

5. Form of disclosure

5.1. Date of publication: 30 June 2026

5.2. Disclosure platform: Pfizer Switzerland www.pfizer.ch

5.3. Disclosure language: English

6. Disclosure of financial data

6.1. Currency: TOV are reported in local currency (CHF). TOVs made in a non-local currency were converted to local currency (CHF) prior to publication. The Pfizer standard exchange rates for the TOV day of payment are applied.

6.2. Value Added Tax (VAT): Treatment of VAT depends on the ToV:

- Where possible in kind related TOV's will be reported including tax.
- Where possible direct payment TOV's will be reported including tax.

6.3. Calculation rules: the disclosure of in-kind or product donations is based on the market value or the book value.

7. Additional information

n/a